A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors
This study is testing a new cancer-fighting medicine called sacituzumab tirumotecan compared to standard chemotherapy for people with a specific type of advanced lung cancer. Researchers want to see if this new treatment helps patients live longer and better than traditional chemotherapy after previous treatments have stopped working.
You may be able to join if you have advanced nonsquamous non-small cell lung cancer with an EGFR mutation that has continued to grow after taking targeted treatments. Your previous treatment side effects must have mostly cleared up, and certain health conditions like Hepatitis or HIV must be well-managed.
Participants will be randomly placed into one of two groups to receive either the new study medicine or standard chemotherapy drugs. You will also receive supportive medications, such as steroids or antihistamines, to help keep you comfortable and prevent side effects.
The study has locations in Oakland, Roseville, and San Francisco, California. Currently, this study is active but not actively recruiting new participants.
- 1Tests a new medicine against standard chemotherapy for advanced lung cancer
- 2Designed for patients whose cancer has progressed after EGFR inhibitor treatments
- 3Currently active at multiple locations in California but not accepting new patients
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.